Crossmark

Phase 2 Open-label, Single-arm, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Camostat Mesylate in Patients with Protein-losing Enteropathy After Fontan Operation

Crossref DOI link: https://doi.org/10.1007/s00246-025-03859-9

Published Online: 2025-04-14

Published Print: 2026-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Park, Woo Young

Kim, Gi Beom

Lee, Sang Yun

Baek, Jae Suk

Kim, Soo Jin

Jung, Jowon

Hyun, Myung Chul

Lim, Young Tae

Lee, HyoungDoo

Ko, Hoon

Lee, Joowon
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct05474664 at ClinicalTrials.gov

Documents that mention this clinical trial

Phase 2 Open-label, Single-arm, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Camostat Mesylate in Patients with Protein-losing Enteropathy After Fontan Operation
https://doi.org/10.1007/s00246-025-03859-9
Funding

Funding for this research was provided by:

SNUH Lee Kun-hee Child Cancer & Rare Disease Project (24C0210100)

Seoul National University
License Information

Text and Data Mining valid from 2025-04-14

Version of Record valid from 2025-04-14
More Information

Article History

Received: 26 January 2025

Accepted: 4 April 2025

First Online: 14 April 2025

Declarations

:

: The authors have no conflicts of interest to declare.

Document is current

Any future updates will be listed below